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Abstract 
A Kinetic Study of anti-VEGF-A Polyclonal Antibodies  
and anti-VEGF-A ssDNA Aptamers 
Heather Hedeen 
A new detection reagent that could possibly augment or replace 
antibodies research and diagnosis methods are aptamers.  Aptamers are ssDNA, 
RNA or polypeptide constructs that function like active antibodies. Antibodies and 
aptamers both specifically bind to selected target molecules, and as such they 
enable the detection or targeting of the presence or absence of a specific 
antigen.  
In order to ensure that ssDNA aptamers perform similarly to antibodies, 
anti-VEGF-A polyclonal antibody and anti-VEGF-A ssDNA aptamer were 
evaluated against vascular endothelial growth factor A (VEGF-A) using Surface 
Plasmon Resonance (SPR). It was hypothesized that the anti-VEGF-A aptamer 
had the same, if not better, binding kinetics than the anti-VEGF-A polyclonal 
antibody, and as such offers an ideal replacement for use in in field, real-time 
testing assays. 
SPR revealed that both the polyclonal antibody and ssDNA aptamer 
bound the target antigen, VEGF-A.  Additionally, from the SPR kinetic analysis, 
the anti-VEGF-A aptamer had KD values of 20-28 nM and the anti-VEGF-A 
antibody had KD values of 16-127 uM. The binding efficacy of the aptamer was 
several orders of magnitude better than that of the antibody. The aptamer was 
also stable in solution for a longer amount of time than the antibody, which 
denatured in solution after two weeks. 
Goals of the thesis: 
• To gain an understanding of SPR instrument use 
• Kinetic analysis of anti-VEGF-A polyclonal antibody 
• Kinetic analysis of anti-VEGF-A ssDNA aptamer 
• Ramifications of kinetic analysis 
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I. INTRODUCTION 
 Biotechnology is a constantly changing field of technical knowledge as 
new techniques and materials are researched and developed. What was once 
the standard in many areas of research is now giving way to these new methods 
and materials that are being created by researchers. Many of these new 
techniques allow for novel diagnostic and analysis procedures that are more cost 
effective and less time consuming than their predecessors. One such shift is that 
from antibodies to aptamers; aptamers offer a new methodology for testing and 
identifying selected analytes. Another advancement in detection technology in 
the last decade is Surface Plasmon Resonance (SPR), which requires a limited 
amount of antigen, even down to the order of femto-moles. However, the lowest 
detectable level is often dependent on the amount of background noise created 
and varies from experiment to experiment based on the molecules used [1]. 
 The research presented here combines aptamers, antibodies, and SPR 
as an analysis technique to support the validity for shifting from antibodies to 
aptamers for use as detection reagents on medical and pathological diagnostic 
platforms. SPR is used to analyze the similarities or differences in the kinetics 
binding between anti-VEGF-A antibodies, anti-VEGF-A aptamers and VEGF-A. It 
is hypothesized that that aptamers have similar or better binding kinetics than 
antibodies do and as such offer ideal replacements as biotechnology seeks to 
produce better in field, real-time testing assays. All together the data gathered 
will be used to help develop a proof-of-concept for utilizing aptamers on 
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diagnostic paper microfluidic testing platforms as an inexpensive, stable and 
reusable platform that may be performed quickly and easily.   
These aptamer detection platform assays will not only affect laboratory 
techniques but will also allow for the production of rapid in-field testing assays for 
use by the FDA, first responders, the HSO, the Navy, and in developing 
countries. 
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II. BACKGROUND 
FUNDAMENTALS OF ANTIBODIES 
Structure and function 
Antibodies play a crucial role in the immune system; they are naturally 
produced by B-cells as part of the humoral immune response to the presence of 
foreign antigens within the body. The structure of antibodies has been 
determined through X-ray crystallography to consist of three globular regions 
assembled into a Y-shape. This Y-shape is composed of two heavy and two light 
chains. The heavy chains are linked together by disulfide bonds into the 
preliminary Y-shape and the two 
light chains are in turn linked to the 
heavy chains at the top of the Y by 
disulfide bonds. Together the light 
and heavy chains make up the 
symmetrically identical Y-shaped 
antibody structure. Antibodies make 
up the most diverse class of proteins 
with all antibodies having a constant 
c-terminus, at the bottom of the Y–
shape, and a variable n- terminus, found at the top of the Y. The n-terminus 
changes for optimal binding to antigens and is unique to each antibody produced. 
When antibodies are exposed to pepsin, they cleave into Fab and Fc fragments. 
The n-terminus is made up of the Fab fragment; it is composed of a complete 
Figure 1: Basic structure of an antibody. 
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light chain and part of the heavy chains on each side. Fab stands for fragments 
of antigen binding and is where the antigen interacts and binds to the antibody. 
The c-terminus is composed of the Fc fragment, or Fragment crystallizable 
fragment, made up by the bottom portion of the heavy chains. The Fc fragment 
does not interact with antigen, but instead interacts with cells and effector 
molecules. Genetic modification can be used to optimize the Fab and Fc 
fragments for binding and interaction between the antibody, antigen and cell 
receptors [2]. Antibodies that are produced for research result from two different 
production techniques, which produce slightly different antibody products: 
monoclonal and polyclonal antibodies.   
Monoclonal antibodies 
Niels Jerne, Georges Kohler, and Cesar Milstein developed monoclonal 
antibody (mAb) production and won the Nobel Prize in Physiology or Medicine in 
1984 for their discovery [3]. Monoclonal antibodies are produced from cell lines 
created from murine derived cells that have been immunized with the desired 
antigen. Cells are either produced through tissue culture or direct injection of 
mice from which the mAb will be processed and purified. mAb production in mice 
is a commonly used technique that is well understood, their use and well being 
must monitored due to Institutional Animal Care and Use Committees. Cell 
culture, while becoming more common, is still not as widely understood and 
using in vivo techniques and is expensive and time consuming.  
mAb production in mice follows five basic steps. Step 1: the mice are 
immunized with antigen emulsified Freud’s adjuvant to encourage an immune 
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response and the production of antibodies at the injection site. The mice are 
immunized every few weeks in order to obtain the desired antibody titer within 
their serum. Step 2: the mice are screened for antibody production by using 
blood samples to measure the level of antibodies in their serum. If the titer in a 
mouse is too low, then the mouse will be inoculated with more antigen. Once the 
titer is high enough in the serum, cell fusion is performed. The mice are injected 
with one final antigen dose three days before cell fusion takes place, but at least 
two weeks after they received their previous immunization. The mice are 
euthanized and their spleen or lymph nodes are removed to produce hybidomas. 
Step 3: preparation of myeloma cells for fusion with the antibody-producing cells 
from the mice. The antibody-producing cells from the mice have a limited lifetime 
whereas the myeloma cells are immortal. When the two cells are combined, they 
result in cells that are capable of immortal growth and continued production of 
antibody. The myeloma cells are cultured with 8-azaguanine so that they will not 
die when exposed to hypoxanthine-aminopterin-thymidine (HAT), which is used 
to positively select for only antibody producing cells that have fused with the 
myeloma. The myeloma cells also have been modified to lack hypoxanthine-
guanine phosphoribosyl transferase (HGPRT-), this means that the myeloma 
cells cannot synthesize purines and in order to survive they need to fuse with the 
normal GHPRT+ mouse cells. Step 4: Fusion of the myeloma and antibody-
producing cells. Fusion between the antibody-producing cells and the myeloma 
cells is achieved by co-centrifuging them at a ratio of 10:1 in polyethylene glycol 
causing cell membranes to fuse. Since the fusion is random, only some of the 
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fused cells are between the antibody-producing cells and myeloma cells. 
Selection for these cells uses HAT media. The aminopterin in the HAT is a folic 
acid analogue that blocks the biosynthesis of purines and pyrimidines, ceasing 
DNA synthesis. Any antibody-producing/antibody-producing fused cells will not 
be able to survive in the HAT media because they cannot synthesize DNA. Any 
myeloma/myeloma-fused cells will die in a few weeks because they lack HGPRT. 
The antibody-producing/myeloma fused cells will have HGPRT provided by the 
antibody-producing cells and the myeloma cells will keep them alive in the HAT 
solution. 500 hybrids that are usually made per mouse spleen and only around 
20 to 30 of those are usable hybrids. The antibody-producing/myeloma fused 
cells are placed into well plates that contain feeder cells, believed to promote the 
growth of hybridoma cells through supplying growth factors. Step 5: cloning the 
hybridoma cell lines. The hybridoma cells from the well plates are grown in tissue 
culture and then selected for based on antigen binding.  
After mAbs are developed, they can be produced in vitro using batch 
tissue-culture or semipermeable-membrane-based system production if the 
specific cell line allows in vitro production.  Batch tissue-culture is used to grow 
hybridoma cultures in batches from which pure mAb can be extracted. Fetal 
bovine serum commonly used as the tissue-culture media however serum-free 
media has been developed to avoid possible contamination. Batch tissue-culture 
methods are low cost, easy to perform, and only take around 3 weeks to produce 
the same quality of mAb as those produced in vivo. However, batch tissue-
culture does not produce high concentrations of mAb, usually below 20ug/ml. 
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While it easy to perform this method, large amounts must be produced to obtain 
usable amounts of antibody. Also, some antibodies denature when they are 
purified and concentrated from the culture during batch tissue-culture. Another 
option for in vitro production of antibodies is semipermeable-membrane-based 
system production. A barrier is used that has a low-molecular-weight cutoff 
allowing for cells to grow at high densities; when hybridoma cells grow at higher 
densities in culture the result is the production of higher amounts of harvestable 
mAb. Semipermeable-membrane based systems make it possible to isolate the 
cells and mAb in the chamber separated from the culture media. This allows for 
supplementation of growth factors to optimize the growth of the hybridomas and 
keeps nutrients for the cells and any undesired cell waste away from the mAb 
product through diffusion. Media can be constantly replaced without losing any 
cells or mAb contained in the small chamber. Semipermeable-membrane based 
systems allow for higher concentrations of mAb to be produced in low volumes of 
culture, however, the mAb may be contaminated by any dead cell products that 
do not diffuse through the membrane.  Semipermeable-membrane-based 
systems are more technically difficult to run than batch tissue-culture methods. 
These two techniques allow for in vitro options that do not involve euthanizing 
animals while still producing functional monoclonal antibodies. The production of 
monoclonal antibodies is necessary for the development and production of 
diagnostic and therapeutic techniques [4]. 
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Polyclonal antibodies 
 Polyclonal antibodies differ from monoclonal antibodies by recognizing 
multiple binding sites for one antigen, meaning that there is a heterogeneous 
mixture of antibodies all with different affinities for the antigen within one sample. 
This causes polyclonal antibodies to be prone to variability between batches, 
unlike monoclonal, which are identical between batches. One reason that 
polyclonal antibodies can be more desirable than monoclonal antibodies is 
because monoclonal antibodies may be too specific to detect an antigen if any 
mutation has occurred [5]. Polyclonal antibody production is similar to 
monoclonal antibody production in that a laboratory animal is used, however, 
various animals may be selected depending on the amount of serum needed and 
how easily it can be obtained. Some animal choices include mice, chickens, 
guinea pigs, goats, and sheep. Antigen is injected subcutaneously, 
intramuscularly, intradermaly, or intraperitonealy in several sites on the animal 
along with an optional adjuvant, to promote the immune response at the injection 
site. Blood is taken from the animal, up to 10% of the blood volume of the animal 
at a time every 3 to 4 weeks from which the antibody is harvested [6]. The blood 
is centrifuged to separate the red blood cells from the serum. An antigen-bound 
sepharose bead column can be used to separate the desired antibodies from the 
other antibodies in the serum solution. The serum is run through the column and 
only the desired antibodies will bind to the antigen-bound beads and all the 
others will run through. The bound antibodies are then eluted from the sepharose 
beads and collected as polyclonal antibodies that all bind to the same antigen. 
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Use in research 
Antibodies are used for many different applications including diagnostic 
analysis and disease targeting. Antibodies can be used as drugs with specific 
targeting; monoclonal antibodies are used to make cancer cells more visible to 
the immune system by attaching to parts of the cancer cells and alerting the 
immune system to attack it.  Antibodies can also be used to block growth signals, 
stop new blood vessels formation, or deliver radiation to specific cancer cells [8]. 
One of the most common techniques involving antibodies is ELISA, which 
is used for determining the presence or absence of diseases such as HIV. ELISA  
(enzyme-linked immunosorbent assay) can be performed several ways, all 
involving the use of antibodies. Firstly, indirect ELISA is performed when the 
target antigen is adsorbed to the bottom of the wells on a plate and antibodies 
extracted from a patient are allowed to interact with it.  Finally anti-human 
antibodies are used to image the plate to determine if there was binding between 
the patient antibodies and the antigen. If binding occurs then the individual has 
that antigen present in body. Indirect ELISA is performed to determine whether 
an antigen is present or not, the second ELISA technique allows for detection 
and quantification of the antigen. The second most common form of ELISA is 
sandwich ELISA. Sandwich ELISA is performed by adsorbing anti-antigen 
antibodies to the bottom of the wells on a plate. The sample from the patient is 
then added to the wells to allow interaction with the antibody. Next, another 
antibody is added that will also bind to the antigen. Finally an enzyme linked 
antibody is added that will interact with the second antibody, the enzyme will 
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produce a detectable signal that will allow for the quantification of antigen present 
[9]. 
 Western blot also utilizes antibodies; specific proteins may be identified 
within the gel through modified antibodies that allow for imaging. Proteins are 
separated by size using SDS-PAGE and then electrophoresis is used to transfer 
them to nitrocellulose paper. A process similar to that in ELISA is used where the 
proteins are incubated with primary antibody and then secondary antibodies that 
allows for visualization and quantification of the amount of protein.  
A relatively new technique for antibody use are microarrays where 
anywhere between 5,000-10,000 proteins can be analyzed at a time. Proteins 
are captured on the chip by specific primary antibodies and then analyzed using 
secondary imaging antibodies. These imaging antibodies are often recombinant 
antibodies that allow for detection by fluorescence, nano-electrodes, and surface 
plasmon resonance [10]. This technique is most commonly used for overall 
proteomic analysis. 
Antibodies are also used for in-field testing that has the advantage of 
being quick, easy to perform, with easily interpreted results. One such test is the 
pregnancy blood test. hCG is present in the blood of pregnant women, an 
immobilized primary capture antibody is used to bind to this molecule and a 
secondary signal antibody is then used to give a response. One important thing 
to note for test like this is the possibility of false positives due to interfering 
antibody interaction. This interaction occurs if the Fab regions on the interfering 
antibody interact with those on the primary and secondary antibodies. This will 
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cause the signaling antibody to indicate a positive, even though no antigen is 
present. Another diagnostic test that has been developed using antibodies are 
blood typing kits. Antibodies are immobilized to the surface of the testing kit, 
when blood interacts with the antibodies it will coagulate if antigen is present. 
Based on which antibodies the blood coagulates with both the blood type and the 
Rhesus factor can be determined. 
As more selective and stable binding between antibodies and antigen are 
required, new antibodies modifications are being developed in the laboratory to 
meet these needs. The Fab segments of antibodies have been mutated in order 
to manufacture antibodies with higher affinity binding. This is achieved by 
improving the contact and molecular interactions between the antibody and the 
antigen [11]. 
Advantages/disadvantages 
There are many different reasons for selecting between monoclonal and 
polyclonal antibodies when performing an experiment. Polyclonal antibodies are 
selected for use when an increased signal is desired since there are various 
antibodies that all bind to the same antigen at different sites. Polyclonal 
antibodies are also less sensitive towards changes in the antigen allowing for 
detection of any mutated antigen. Monoclonal antibodies, on the other hand, are 
selected when highly specific binding is needed between antibody and antigen. 
Since mAbs are produced by hybridomas more quantity can be produced of 
identical and pure antibodies. However, polyclonal antibodies are much less 
expensive to produce than monoclonal antibodies and require a lower level of 
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technology and skill. Polyclonal antibodies also take significantly less time to 
produce than monoclonal antibodies do. 
There are also advantages and disadvantages to utilizing antibodies 
instead of other molecules. Antibodies cannot easily be produced for toxins due 
to the fact that they are produced in animals that cannot tolerate them long 
enough to produce an antibody for them. Another restriction of antibodies since 
they are produced to function in cells is that for diagnostic techniques, antibodies 
are often not able to function in non-physiological conditions. Since antibodies 
have complex, protein based structures they are denatured easily due to 
temperature, susceptible to oxidation or deamidation, degradation or 
aggregation, leading to a limited shelf life. 
FUNDAMENTALS OF APTAMERS 
Production 
 Aptamers are produced through a method called the SELEX (systematic 
evolution of ligands by exponential enrichment) process. This process begins 
with a random sequence oligonucleotide library that is obtained by combining the 
four nucleotide building blocks, adenine, thymine, guanine, and cytosine for DNA 
and adenine, cytosine, guanine, and uracil for RNA.  Depending on if a RNA or 
DNA aptamer is being created, the specific four nucleic acids molecules are 
added together in a concentration based on the coupling efficiency of each 
individual monomer. A fixed sequence is used as a primer for binding 
amplification of the oligonucleotide sequences. The length of nucleotide positions 
in the random region determines how complex the oligonucleotide library will be; 
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for example, if a library has a “40-nucleotide random region” the library will 
contain up to 1.2X1024 different sequences. However, a library is typically limited 
by chemical synthesis to only contain around 1014-1015 sequences [12].  
Once a random library is synthesized, it is exposed to the target of interest 
for which the aptamer is being designed. The target of interest is bound to 
nitrocellulose paper prior to being exposed to the oligonucleotide sequences so 
that all non-binding sequences can then be washed off, leaving the bound 
sequences to attached to the target on the nitrocellulose paper. Once the 
unbound sequences are washed off, the bound sequences are eluted and 
amplified using PCR for creating a DNA aptamer or RT-PCR for an RNA 
aptamer. The binding and amplification process is repeated in order to increase 
the affinity for the bound molecules. Typically around 8-15 cycles of affinity 
enrichment are performed, taking around 2-3 months to produce high affinity 
binding aptamers. The SELEX process creates aptamers that over 90% of the 
time are able to bind to the target and are around 70-80 nucleotides in length 
[12]. These sequences can be paired down from the 70-80 nucleotide length to 
cut out any areas that do not play an important role in the three dimensional 
structure of the aptamer for binding with the target molecule.   
After aptamers are fully developed through the SELEX process, they can 
be produced in less than 3 days, resulting in identical product each time. Another 
step may be added to the SELEX process resulting in counter-SELEX where 
aptamers can be counter selected for. This comes in useful when creating an 
aptamer that will bind to a cell, but only those that display a particular 
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characteristic, such as being infected with cancer.  Counter-SELEX is 
accomplished by eliminating any oligonucleotides that have affinity for motifs 
present on non-targeted cells. 
Structure 
 Aptamers are composed of either ssDNA or RNA that are usually 70-80 
nucleotides in length. The aptamer folds into a three dimensional structure that 
will interact with the antigen of choice, much like an antibody does. The molecule 
that interacts with the aptamer is called a ligand and aptamers are designed to 
specifically bind to one and only one ligand. 
 RNA structure is determined by the primary, secondary, and tertiary 
interaction that it undergoes. Primary structure is determined by the nucleotide 
sequence that makes up the RNA strand. The secondary structure of the RNA is 
determined by the two-dimensional interactions between the individual 
nucleotides that make up the RNA. For RNA common secondary structures are 
duplexes, single-stranded regions, 
hairpins, bulges, internal loops, and 
junctions (Figure 2) [13]. The tertiary 
structure of RNA is determined by the 
interactions between the different regions 
of the two-dimensional secondary 
structures of the RNA strand that make 
up the three-dimensional shape of the 
molecule. Some examples of common 
Figure 2: RNA Secondary Structures 
Some of the common two-dimensional 
secondary structures of RNA. (Figure from 
Batey, Robert T. et al.) 
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tertiary interactions are triple interactions: the RNA single strands interact with 
double-stranded RNA complexes through hydrogen bonding, pseudoknots: form 
where the RNA nucleotides in a hairpin loop pairs with a single stranded region 
of RNA, kissing hairpins: formed when unpaired nucleotides from one hairpin 
loop interacts with another unpaired nucleotide in another loop [14].  
 The structure of RNA allows for reversible denaturation, meaning that the 
tertiary and secondary structures are no longer formed when the RNA molecule 
is exposed to an atmosphere that facilitates denaturation. Once the denaturing 
climate is removed, the RNA will fold back into its original form with the 
secondary and tertiary structures (Figure 3).  One issue with RNA aptamers in 
regard to their structure is the ability of nucleases to degrade the RNA; therefore 
modifications have been developed to protect the RNA aptamers. Modifications 
have be made to the 2’ position on the pyrimidine nucleotides by adding –F or -
NH2 functional groups to prevent denaturation by nucleases.  
 Another solution to the degradation of RNA aptamers is to use a single 
stranded DNA aptamer instead.  Single stranded DNA (ssDNA) acts much like 
RNA in that it is able to interact with itself to form into two and three-dimensional 
shapes through interactions. ssDNA will form secondary structures just like the 
Figure 3: Reversible denaturation pathway of RNA 
 On the far right the RNA is completely denatured, slowly the secondary structures resulting from 
the interactions between the nucleotides are achieved. Finally on the far left the tertiary structures 
are completed, resulting in the three-dimensional shape of the RNA. (Figure from Batey, Robert T. 
et al.) 
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RNA aptamers: internal loops, hairpin loops, bulges, dangling ends, terminal 
mismatches, coaxial stacking, and multibranched loops [15]. It has been 
suggested that ssDNA tertiary structure is based on the guanine quadriplex 
structure, which is part of the secondary aptamer structure and is made up of 
one, two, or four oligonucleotide strands [16]. DNA aptamers are also suspected 
to have a partially disordered tertiary structure when no antigen is bound [17]. 
Furthermore, in a thrombin aptamer study, it was indicated that due to the fact 
that the tertiary structure of aptamers is highly specific, is very important for the 
binding interaction with the ligand [18]. 
 Modifications are often made to the structures of both RNA and ssDNA 
aptamers in order to increase their usefulness in laboratory techniques or to 
increase stability. The increase in RNA stability has already been discussed; this 
is achieved through producing the aptamers from libraries that contain the 
modified pyridinines instead of normal ones. Other modifications that have been 
developed are made at the C-5 position on the pyrimidines and include the 
addition of –I or –Br for photo or chemical crosslinking, -SH for chemical 
crosslinking, and amino acid side chains for chemical dressing [12]. 3’-end caps 
have also been added to aptamers in order to reverse their polarity, and as such 
preventing any 3’ exonuclease activity. PEG is also added to the 5’ end of 
aptamers to extend the in vivo half-life of aptamers [19].  One interesting result of 
modification is that the primary and secondary structures of the aptamers are 
significantly changed from those produced without the modifications.   
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Use in Research 
The structure of aptamers allows them to bind to target molecules or cells 
with high affinity and specificity. Aptamers have so far been developed for targets 
such as metal ions, organic dyes, drugs, amino acids, co-factors, 
aminoglycosides, antibiotics, nucleotides, and peptides [12]. One specific use for 
aptamers is their utilization for lead detection in the environment; gold 
nanoparticles are coated with engineered molecules made up of a 12-mer 
aptamer, a DNAzyme, and a substrate. In the absence of lead, the substrate 
hybridizes with the aptamer causing the gold to aggregate, resulting in a blue 
color. If lead is present, then the DNAsyme catalyzes hydrolytic cleavage of the 
substrate so that the aptamer is no longer able to bind. This prevents the 
aggregation of the gold and produces a red color. UV-vis spectroscopy is used to 
detect these color changes as well as to quantify the amount of Pb2+ present in 
the sample [20]. 
Aptamers have also been modified using Photo-SELEX to create 
aptamers that are capable of simultaneous quantification. During the SELEX 
process modified nucleotides are used that can be activated by the absorption of 
light. Aptamers made up of these nucleotides covalently bond with their target 
when activated by light, leading to greater sensitivity and specificity. Chips have 
been made using Photo-SELEX-evolved aptamers that are incubated with 
extremely dilute sample and can allow for imaging and quantification of the 
sample [21]. 
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Counter-SELEX has already been used to develop an aptamer against 
glioblastomas, one of the most common brain cancers. Aptamers such as this 
can be used as molecular probes for the detection, characterization, and isolation 
of tumor cells when they have been modified with fluorescent labels. Aptamers 
have successfully been used to target and identify cells within bone-marrow 
aspirates [22]. 
Aptamers have also been developed as drugs that target specific 
molecules. In 2004, Macugen was developed and approved by the FDA as a 
drug against age-related macular degeneration. As of 2012, Macugen is still the 
only aptamer based therapeutic that has been approved for market by the FDA. 
Macugen is an RNA aptamer the binds to all isoforms of VEGF.  There have 
been other attempts to develop antigen-based drugs such as an antidote-
controlled anticoagulant RNA aptamer. This aptamer drug functions by using an 
aptamer that elicits an anticoagulant effect by binding and inhibiting the activity of 
coagulation factors. A complimentary aptamer region was also developed that 
upon injection binds and neutralizes the active form of the drug. The drug went to 
phase 1 of clinical trials but the study was terminated because the protocol 
defined safe threshold was exceeded in one subject who received the highest 
dosage [23]. 
Aptamers have also been used in techniques such as flow cytometry and 
immunosensors, taking the place antibodies. Aptamers are showing promise to 
be used as sensors based on electrochemical detection; since aptamers are 
polyanionic they can be used to sense changes in conduction based on the 
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presence or absence of a target molecule. One study used this technique to 
develop a microfluidic electrochemical aptameric assay integrated on a chip that 
was able to detect selected targets in a mixed sample with no interference [24]. 
Other areas of research where aptamers have begun to take hold are as 
molecular switches, for detection of proteins (being referred to as “Eastern 
blotting” completing the blotting technique quadruple), aptamer arrays for 
proteomic analysis, and many other clinical applications for disease drug 
analysis. 
Advantages/disadvantages 
 Aptamers offer an alternative to traditional molecular choices such as 
antibodies. Aptamers offer an advantage over antibodies because they can be 
created for any molecule, even those that are toxic to biological systems. 
Aptamers also allow for a plethora of modification options, from making them 
more detectable to changing the kinetic on- and off-rates, something much more 
difficult to do with antibodies [12]. Aptamers offer high reproducibility, meaning 
that there is little to no batch-to-batch variability. Due to the nature of RNA and 
ssDNA, aptamers are able to undergo reversible denaturation. This reversible 
denaturation holds one of the highest advantages of aptamers over antibodies as 
it offers for production of reusable diagnostic testing platforms, further lowering 
the cost of production. Products such as this would be ideal for in field-testing; 
especially in third world countries where clinical analysis is difficult and cost is a 
huge factor.  Aptamers are also much more cost effective to produce than 
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monoclonal antibodies are, taking around the same amount of time with little to 
no hands-on interactions needed and less experienced lab technicians required.  
 So far one of the only major limitations that has become apparent for 
aptamers is the vulnerability of RNA aptamers, but the aptamer may be modified 
as talked about previously to compensate for this. SELEX can also be laborious 
to carry out, however, automated systems now exist that are faster and more 
economical that require little to no human intervention that can run multiple 
SELEX experiments at a time.  
Another current disadvantage to the use of aptamers is the fact that their 
invention was still less than 20 years ago so many of the applications and 
production techniques related to aptamers are still protected under patents. 
Gilead Science acquired many of the patents that are related to the SELEX 
process as well as the actual aptamer structures that have been produced [25]. 
The length of patent protection is 20 years after filing takes place so the first of 
their patents, filed in 1992 will expire this year along with several other patents in 
the coming years.  Archemix is another company that has intellectual property 
rights to aptamers, specifically to the exclusivity to use of them in therapeutic 
applications [25]. The first of their patents was filed in 2002 so their patents will 
not begin to expire until 2022. However, they have licensed out the rights of their 
patents to several other companies to use in the research and develop other 
therapeutic applications. SomaLogic has exclusivity to the use of aptamers for 
diagnostic applications [25], with their first patent filed in 1999 and expiring in 
2019.  Since many of the patents initially filed that relate to aptamers are starting 
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to expire, there is a high likelihood that new applications for aptamers will 
continue to be developed in upcoming years that involve previously patent 
protected techniques.  
 An alternative to both aptamers and antibodies that are also being 
researched are molecular imprinted polymers (MIP).  A MIP is a polymer that is 
made using a three dimensional template that is then removed, leaving behind a 
three-dimensional polymer with complimentary spaces from where the template 
was removed.  Unlike both aptamers and antibodies, MIPs are made of entirely 
synthetic products making them even more stable than aptamers are with the 
ability to withstand high temperatures, pH ranges, and long-term storage.  MIPs 
have the ability to recognize and bind to specific target molecules and offer 
another option besides antibodies and aptamers that have to for use in many 
techniques that currently employ antibodies [25]. 
FUNDAMENTALS OF SURFACE PLASMON RESONANCE (SPR) 
Surface Plasmon Resonance History and Theory 
 R.W. Wood first discovered the theory behind surface plasmon resonance 
in the early twentieth century with his work on diffraction on diffraction gratings 
due to the excitement of surface plasmon waves. Kretschmann and Otto 
continued to research surface plasmons through optical excitation in the 1960s. 
Since 1992 the amount of research publications that mention the use of SPR has 
exponentially grown each year from only a handful in 1992 to over 500 in the first 
half of 2006 [26]. 
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Surface resonance is a charge-density oscillation that occurs at the 
interface of two media that have opposing dielectric constants [27]. This 
oscillation results in a surface plasmon wave. Surface plasmon waves are TM-
polarized waves, meaning that the magnetic vector is perpendicular to the 
direction of the propagation and parallel to the plane of the interface. Surface 
plasmons are the collective oscillations made by the free electrons in a metallic 
film. When exposed to specific conditions, the surface bound plasmons will 
resonate with light, resulting in the absorption of the light. These conditions are 
extremely sensitive with respect to the refractive index of the medium that is 
located adjacent to the metallic film, which means that the presence of any 
molecules on or near the surface of the film can easily be detected.  
One common method used to excite the surface plasmons into their 
resonance oscillations is the Kretschmann configuration that uses a p-polarized 
laser and a metal film, typically gold or silver. The incident angle reflection of the 
laser on the metal film is used to achieve the resonance of the surface plasmons. 
When the incident angle is small and resonance is occurring, the incident light 
may be absorbed by the metal film resulting in a low intensity of reflection. This 
means that the reflected light remains at 
a high intensity for a large range of 
angles except at the resonance angle.  
In order to find the resonance angle, θR, 
Equation 1 is used. ε1 can be water, air, 
or a variety of other solvents or 
Equation 1: SPR resonance angle 
Used to calculate the resonance angle, θR. 
ε2 is the dielectric constant of the prism, εm 
is the real part of the dielectric constant of 
the metal film, ε1 is the dielectric constant of 
the testing medium to which the metal film 
faces.  
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solutions, often for biological SPR experiments PBS buffer is used.  A shift in θR 
occurs then there are molecules near or on the surface of the metal film. The 
shift in the resonance angle is proportional to the amount of molecules that are 
adsorbed on the metal film surface, through observing the changes in the 
resonance angle it is possible to measure the association, disassociation, and 
affinity binding constants for the molecules [27]. 
SPR Components and System 
 BIAcore AB released the first commercially available SPR system in 1990 
and since then several other companies have also developed and released 
commercial SPR systems. Each SPR machines, no matter which company 
produced it, has the same basic components and systems as they all perform 
analysis using the same basic theory.   
The main difference between SPR systems is how automated they are 
and how many analysis channel 
exist; these two components 
both directly relate to the cost of 
the SPR system. The main 
components in all systems are 
the flow cell through which the 
sample and running buffer flow. 
There is a prism (Figure 4) on 
which the metal film chip is 
placed, often with a specific 
Figure 4: Surface Plasmon Resonance 
Shows the interaction of the molecules and their 
effect on the metal film surface and the resulting shift 
in reflected light from the laser. This shift is translated 
to graphical data allowing for analysis of the kinetic 
interactions on the molecules. (Figure from B!-2000 
SPR Manual v5.4) 
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molecule, the ligand, immobilized on the surface. The binding or interacting 
molecule to the ligand is injected into the buffer solution as it flows across the 
surface of the functionalized metal chip surface. As the ligand and its conjugate 
interact the refractive index will change, this change is measured and imputed 
into the system’s software that analyses it and shows the mDeg change in the 
angle of refraction. This information can be further analyzed to give the kinetic 
data for the interaction between the ligand and the interacting molecule [29]. 
 Due to the sensitivity of SPR, all liquids that are run though the system 
must be either sonicated or degassed to remove any dissolved gas molecules in 
the solution. When injecting samples into the machine care must be taken to 
avoid gas bubbles in the injection syringe as well. Dissolved gasses in the 
solution will result in random spikes in the sensorgram that will interfere with the 
results. Care must also be taken when cleaning and preparing the prism surface 
before placing the chip on it. If the prism is scratched at all, the refraction angle 
will not be able to properly observe molecular interactions taking place. The flow 
rate of the buffer should not exceed 150uL/min or there is not enough time for the 
kinetic or equilibrium constants to be extracted from the flow data [28]. The flow 
rate cannot be too slow either or mass transport limited kinetics will occur [28]. 
Use in research 
 SPR has been used in several areas of research including for the 
measurement of physical quantities of materials, for chemical sensing analysis, 
and for biosensing analysis. SPR was first used in 1983 for biosensing analysis, 
and in 1994 the first real-time biospecific interaction analysis was developed [27].  
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SPR provides detection and analysis for chemical, biochemical, and biological 
substances in the areas of medicine, environmental analysis, and drug and food 
safety. One advantage of using SPR is that it is a label-free process that still 
allows for the analysis between molecules. Another huge benefit of using SPR in 
analysis is that only a very small amount of sample is required and machines 
offer real-time analysis and the use of multi-channels for the analysis of 
simultaneous samples.  
 SPR has been utilized to perform microscopy as SPRM or SPR imagine 
(SPRI). SPRI allows for the measurement of DNA and RNA binding to DNA 
arrays or DNA-binding proteins to dsDNA arrays, proteins to protein and peptide 
arrays, and ligands to protein arrays. SPRI can determine the on- and off-rates 
and the equilibrium binding constants for all of these interactions simultaneously, 
sometimes on the order of more than 1,000 at a time. This technique offers cost 
and time efficient detection and analysis technique [30]. SPRI is accomplished by 
spotting probe molecules onto the analysis surface, this must be done in a way 
that will not denature or inactivate the probe, will enable the probe to survive 
washing for multiple use, and makes the probe available for other molecules to 
interact and bind to.  There are many different methods and materials that have 
been developed to functionalize the surface of SPR chips. 
 The first method that is commonly used to attach molecules to the surface 
of SPR chips is through thiol-linking the molecule directly onto the gold metal 
film. Attachment of molecules to the gold surface through thol-linking is achieved 
by exposing the gold surface to thiol-alkane linked molecules and allowing 
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chemisorption to occur; this binding is vey stable and allows for complex media 
buffers to be used [31]. Another common immobilization method is achieved by 
using carboxymethyl dextran (CM-Dextran) that forms a self-assembled 
monolayer (SAM) onto which other molecules can easily be bound. An activating 
kit is used to activate the dextran surface and allows for amine coupling occurring 
between the dextran particles and the molecules will become immobilized on the 
surface.  Other chemical attachments and surface modifications that are used 
include aldehyde coupling, streptavidin-biotin linking, silicate and silicon 
functionalized surfaces, and biocoatings [32]. 
 SPR has become a common laboratory technique to observe the binding 
kinetics between modified antibodies and aptamers and the ligands they were 
created to bind to. The VEGF-binding affinities for the Fab fragments of 
antibodies were observed in an experiment that was attempting to select for 
optimized binding in a modified anti-VEGF antibody [33]. Similarly SPR was used 
when screening for an improved anti-VEGF DNA aptamer. Using SPR not only 
allowed for kinetic analysis of the binding between the aptamer and VEGF, but it 
was also used to observe the role that KCl played in the three-dimensional shape 
of the aptamer [34].  
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III. MATERIALS AND METHODS 
SPR CALIBRATION AND TECHNIQUE 
 The SPR instrument must be calibrated every couple months in order to 
align the signals given by each microfluidic channel so that they are identical. 
This calibration was done using a 1% ethanol solution and by comparing the 
measured mDeg response 
in each channel to the 
expected response 
changes using Equation 2.  
Gloves were worn for the entire experiment to avoid contamination of the 
machine and exposure to the solutions. The 1% ethanol solution was made by 
adding 0.1mL of 99% EtOH to 10mL of DI H2O, both the EtOH and DI H2O were 
previously degassed for an hour in a bell jar apparatus to remove any dissolved 
gases in the solution. The SPR machine was then prepared for use. Two 10mL 
syringes were filled with the DI H2O as running buffer and placed in the Syringe 
Cradle and fastened with the Retainer Bar. The Drive Bar was adjusted to just 
barely touch the end of both syringes. Finally the syringes were screwed into the 
flow tubing.  
Next the prism surface was prepared for a new chip. There was an old 
chip still on the prism surface that was maneuvered using a cotton swap so that 
the prism was not scratched and then tweezers were used to fully remove the 
chip.  To clean the prism surface 99% EtOH and cotton swabs were used. The 
cotton swab was soaked in EtOH and then moved in a spiral pattern around the 
Equation 2: SPR calibration  
Used to calculate the new values to calibrate the channels 
in the SPR machine. 
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prism surface starting in the middle and working outwards. This process was 
repeated until the prism surface was completely clean. The Flow Cell channels 
were also cleaned using EtOH and cotton swabs. Mounting the SPR chips on the 
prism was achieved by placing a small drop of index matching oil in the center of 
the prism. The drop should be only 3-5uL or it can leak out from under the chip 
and contaminate the experimental results. To ensure the drop was the right size, 
the initial few drops of oil were dabbed off onto the rim in the bottle and then the 
glass transfer rod was lightly placed above the prism until as small drop was left 
on the prism. The chip was inspected to determine which side was gold and 
which side was glass, this was achieved by lightly scratching the edge of both 
sides of the chip. The gold side of chip showed scratch marks and the glass side 
did not, the chip was then placed on top of the prism. To ensure no gas bubbles 
were trapped between the chip and the prism, one side of the chip was placed 
down before the other using tweezers. A cotton swab was then used to move the 
chip around slightly. The Flow Cell was then moved into place on top of the chip. 
The machines were then turned on and the flow rate of the running buffer was 
set to 150uL/min to force out any trapped air bubble in the tubing. After ~5 
minutes the flow rate was reduced to 50uL/min and the laser was turned on. To 
make sure that there were no air bubbles in the flow cell there is a viewing 
window that should show two similar SPR dark lines about 4mm wide each. This 
was observed and the machine was allowed to warm up for around 30 minutes, 
until signals in both channel 1 and channel 2 were flat.  
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The calibration was then performed. The machine was placed into serial 
mode. The default calibration value is 3,000; this value was used as an initial 
calibration to run the first 1% ethanol injection. The expected mDeg result was 
supposed to be 60. The injection was made using a 200uL syringe and injecting 
around 150uL of sample into the Injection Valve. The valve was then turned to 
the ‘Injection’ position until the countdown on the computer reached 15 seconds 
left out of 96, when it was switched back to ‘Load.’  After each injection of 1% 
ethanol Equation 2 and the mDeg measuring software was used to find the 
adjusted calibration value for each channel until they both were 60mDeg.  
 In order to get a feel using the instrument and the software an additional 
ethanol dilution experiment was performed after the machine was calibrated. Two 
additional solutions of ethanol were made along with the 1% ethanol solution: a 
0.25% solution and a 0.0625% solution.  The 0.25% solution was made by 
pipetting 1mL of the 1% ethanol solution into 3.01mL of DI H20 and the 0.0625% 
solution was made by pipetting 1mL of the 0.25% solution into 3.0025mL of DI 
H20. These solutions were injected into the machine the same way as the 1% 
ethanol solution was and the results were saved so that they could be analyzed 
using the kinetic software. 
SELECTION OF CARBOXYMETHYL DEXTRAN 
 Carboxymethyl Dextran (CM-Dextran) is a polyanionic derivative of 
Dextran. Dextran is composed of α (16) linked glycan that has side chains 
attached to the 3- positions of the backbone glucose units [35]. CM-Dextran 
allows for molecules to be immobilized on its surface though amine coupling. The 
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CM-Dextran chips were ordered from Biosensing Instrument and stored at -20°C. 
Activation kits for the CM-Dextran Sensor Chips were also ordered from 
Biosensing Instrument and stored at -20°C as well. 
USE OF VEGF 
 VEGF-A is a member of the PDGF/VEGF growth factor family and codes 
or a protein that acts on endothelial cells with various effects. Some of these 
effects include: increased vascular permeability, induction of angiogenesis, 
vasculargenesis, promotion of cell migration, and inhibition of apoptosis [36]. 
 VEGF-A was one of the molecules for which both aptamers and 
antibodies have been developed, making it a perfect molecule for comparing the 
kinetic interactions between it and both its aptamer and antibody conjugates.  
The VEGF-A, also known as VEGF 165, was ordered from Syd Labs as 
recombinant human VEGF 165. This molecule was produced in HEK 293 derived 
cells and had a molecular weight of 19.2kDa. The stability of the VEGF-A was for 
12 months if stored as -20°C to -70°C in evaporated form, 1 month after 
reconstitution if stored at 2°C to 8°C in sterile conditions and for 3 months after 
reconstitution of stored at -20°C to -70°C under sterile conditions [37].  
 The VEGF was diluted to a 25nM solution, a 50nM solution, and a 150nM 
solution. 10.417mL of DI H2O was added to the 10ugram of VEGF sample to 
create a 50nM stock solution. The 50nM solution was then diluted to half by 
adding 1M PBS buffer to create the 25nM solution. The 150nM solution was 
produced by adding 2uL of 1.5mg/mL VEGF solution to 1037.67uL of 1M PBS 
buffer. 
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IMMOBILIZATION OF VEGF AND ANTIBODY/APTAMER INTERACTIONS 
 VEGF-A was immobilized to the CM-Dextran surface in order to observe 
the kinetic interactions between it and the anti-VEGF aptamer and anti-VEGF 
antibody.  The solutions were made at a concentration of between 25 and 100nM 
due to the fact that the SPR machine is extremely sensitive to samples and only 
a small amount is required. Typically concentrations used for immobilization are 
between 10-100nM. 
Antibody Solution 
 The anti-VEGF-A antibody was ordered from Bioss and was a rabbit anti-
VEGF-A polyclonal unconjugated antibody. The antibody was stored at -20°C, a 
temperature where it would be stable for at least one year.  The anti-VEGF-A 
antibody solution was prepared in three concentrations: 100nM, 50nM, and 
25nM. The 100nM solution was made by pipetting 2222.22uL of DI H2O with 
100ugram of the anti-VEGF antibody. The 50nM concentration was made by 
pipetting 1mL of the 100nM solution into 1.5mL of DI H2O. The 25nM solution 
was made by pipetting 1mL of the100nM solution into 3mL of DI H2O. Once 
reconstituted, the antibody was stored at 2-4°C, a temperature where it was 
stable for at least two weeks [38]. 
Aptamer Solution 
 The anti-VEGF-A aptamer sequence was taken from Nonaka et al. from 
when they searched for an improved anti-VEGF-A DNA aptamer. The sequence 
of the aptamer from the 5’ to 3’ end was 28mers long: 
GCACTCTGTGGGGGTGGACGGGCCGGGT; it was ordered from Eurofins and 
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stored at -20°C .The aptamer was unconjugated with no modifications and 
already in a reconstituted solution of 43.79ug/uL. Three concentrations of the 
anti-VEGF-A DNA aptamer were made: 100nM, 50nM, and 25nM. The 100nM 
solution was made by pipetting 1uL of the 43.79ug/uL solution into 48.996mL of 
DI H2O. . The 50nM concentration was made by pipetting 1mL of the 100nM 
solution into 1.5mL of DI H2O. The 25nM solution was made by pipetting 1mL of 
the100nM solution into 3mL of DI H2O. The solutions were stored at 2-4°C. 
pH of VEGF-A Solution 
 The pH of the VEGF turned out to be an important factor for the 
immobilization of the VEGF onto the CM-Dextran. Initially after the 50nM VEGF-
A solution was mixed the pH was ~7.0. However due to the isoelectric point of 
both the VGEF-A and the CM-Dextran, at this pH the VEGF-A was not able to 
immobilize on the CM-Dextran surface.  Ueda et al. performed an experiment 
with VEGF-A and used a pH of 4.5 [39], so the pH of the solution was adjusted 
accordingly. A 20mM solution of HCl was made to adjust the pH of the VEGF-A 
solution as well as a pH probe. To make the 20mM HCl solution 10uL of 6M HCl 
was added to 2990uL of DI H2O. Initially this process was carefully calculated out 
but the 1M PBS buffer resisted the change in pH so much more HCl had to be 
added to reach the desired pH. The pH of both the 25nM and 150nM VEGF-A 
solutions were adjusted to ~4.5. 
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Other solutions 
 To regenerate the surface of the VEGF-A functionalized CM-Dextran chip 
a 20mM solution of NaOH was used. A 1M NaOH solution made by adding 1 
gram NaOH to 1L DI H2O; this solution was then diluted down to 20mM.  
EXPERIMENTS 
 Before any experimental SPR runs were carried out all solutions utilized 
were degassed for 1-2 hours to remove any dissolved gases in the solutions. The 
machine was also cleaned and prepared with the same steps as in the 1% 
ethanol calibration experiment. CM-Dextran chips were used and 1M PBS 
running buffer. The flow rate of each experiment varied. 
Run 1 
 The first SPR run used the pH ~7.0 50nM VEGF-A solution, and the anti-
VEGF-A antibody solutions and the anti-VEGF-A DNA aptamer solutions. The 
surface of the CM-Dextran was prepared for immobilization by using an 
activation kit bought from Biosensing Instrument. For this run all activation 
solutions were mixed before degassing took place. A 0.1M N-
hydroxysulfosuccinimide (NHS) solution was made by adding 0.5mL DI H2O to 
the provided vial. A 0.4M 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) 
solution was made by adding 0.5mL DI H2O to the provided vial. A 1.0M Ethanol 
Amine (EA) solution was also made by adding 1mL of DI H2O to the provided 
vial. After all solutions were degassed and the SPR machine was loaded with 
running buffer and a new CM-Dextran chip and completely warmed up the CM-
Dextran chip was activated and the VEGF-A was immobilized. The flow rate of 
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the running buffer was set to 30uL/min. The 0.1M NHS and 0.4 M EDC were 
mixed together and immediately 100uL were injected into the flow to activate the 
CM-Dextran surface. Immediately after the activation signal finished, the 50nM 
VEGF-A solution was injected followed by the 1M EA solution in order to block 
the CM-Dextran surface. This whole process was performed in serial mode. The 
order of the injections was: 50nM antibody, NaOH, 50nM aptamer, NaOH, 
100nM antibody, NaOH, 25nM antibody, NaOH, 50nM antibody,  
Run 2 
 To help the VEGF-A immobilize to the CM-Dextran surface the pH of the 
VEGF-A solution was changed to 9. The isoelectric point of VEGF-A was either 
8.5 [40] or 9.22 [41] so a pH between the two was chosen. The surface of the 
CM-Dextran was prepared for immobilization by using the activation kit bought 
from Biosensing Instrument. For this run the activation solutions were mixed after 
degassing took place and immediately before injection into the machine. Once 
the NHS/EDC solution was used to activate the CM-Dextran solution, the 25nM 
VEGF-A solution at pH 9 was injected a few times. The order of the injections 
was: 50nM antibody, NaOH, 50nM aptamer, NaOH, 100nM antibody, NaOH, 
25nM antibody, NaOH, 50nM antibody, NaOH, 100nM antibody, NaOH, 100nM 
antibody. All injections after immobilization took  
Run 3 
 The third SPR run used the pH ~4.5 25nM VEGF-A solution, and the anti-
VEGF-A antibody solutions and the anti-VEGF-A DNA aptamer solutions. The 
surface of the CM-Dextran was prepared for immobilization by using the 
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activation kit bought from Biosensing Instrument. For this run all activation 
solutions were mixed after degassing took place. The CM-Dextran surface was 
activated with NHS/EDC solution and then three injections of VEGF-A at pH 4.5 
and one injection of VEGF-A at 9.3 were run. The CM-Dextran chip was then 
blocked using the EA solution. The order of the injections was: 50nM antibody, 
NaOH, 50nM antibody, 50nM antibody, NaOH, 100nM antibody, NaOH, 100nM 
aptamer, NaOH, 50nM aptamer, NaOH, 25nM antibody, NaOH. After the final 
NaOH a few other injections were carried out but they were distorted by an air 
bubble in the system and therefore discounted. All injections after immobilization 
took place were performed in single mode. 
Run 4  
 Since the prior SPR run did not allow for the kinetic analysis software to 
be used another SPR run was performed. In order to quantify the data the two 
channels had to be calibrated to give the same singles, this was achieved 
through using a 0.5M PBS buffer solution and Equation 2. The average in the 
initial channel readings was taken and used as the expected value. Once the 
calibration was finished the CM-Dextran surface was activated with NHS/EDC 
solution and three injections of pH 4.5 25nM VEGF-A was injected. After 
immobilization of VEGF-A, EA was injected to block the CM-Dextran. Only 
channel 2 was immobilized with VEGF-A using single mode injections. NaOH 
was injected to remove any remaining VEGF-A molecules and then the machine 
was switched to serial mode and the sample injections were made. The order of 
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the injections was: 100nM antibody, NaOH, 100nM antibody, NaOH, 100nM 
aptamer, NaOH, and 100nM aptamer.   
Run 5 
 Since the antibody did not work in run 4, the SPR run was a fifth time. A 
0.5M PBS buffer calibration was done for the new dextran chip before 
immobilization took place. The surface of the CM-Dextran chip was activated with 
NHS/EDC solution and the pH ~4.5 150nM VEGF-A solution was injected four 
times in single mode into channel 2. The EA solution was then injected to block 
the CM-Dextran and NaOH was used to wash away any remaining VEGF-A 
molecules. The order of the injections was: 100nM aptamer, NaOH, NaOH, 
100nM antibody, NaOH, 80nM antibody, and NaOH. At this point an air bubble 
disrupted the experiment to the point it could not be continued. 
ANALYSIS SOFTWARE  
 The BI-Data Program allows for analysis of the results recorded by the 
computer during the SPR runs. Selected data is transferred from the BI-Control 
to the data analysis program where several steps were performed with it. The 
program can zero the data responses, crop data, align curves, subtract reference 
responses, and calculate the kinetics of the data.  First the curves to be analyzed 
were selected, one as reference (the channel where no VEGF-A was 
immobilized) and another (the channel where the VEGF-A was immobilized).  
The data was then zeroed to align the curves and cropped to the area of interest. 
Next the reference channel was subtracted from the other channel to give the 
actual interaction curve between the VEGF-A and the anti-VEGF-A antibody and 
 37
anti-VEGF-A aptamer. Next the kinetic analysis was used to fit a curve to the 
data from which km, ka, and kd were calculated, as well as Rmax. For the ethanol 
dilutions an additional step was added that allowed for an affinity curve to be 
calculated using the various concentrations.  
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IV. RESULTS 
ETHANOL DILUTIONS 
 The ethanol dilutions were used to both calibrate the SPR machine and to 
get a feel for the experimental 
process and analysis software. 
Figure 5 shows the relationship 
between each of the ethanol 
dilutions.  The mDeg difference 
for the 1% ethanol solution was 
used in the calibration of 
channels by being fit to a 60mDeg 
curve. The 0.25% ethanol solution 
when measured in both channel one and channel two was equal to ~15.41mDeg. 
The 0.0625% ethanol solution had a change of 4.2mDeg when averaged across 
the two channels.   
 These three concentration curves were put into the software analysis 
program and the kinetics and affinity relationships between the ethanol and the 
gold surface of the chip were calculated two ways. The program was first used to 
find the kinetics: a line was fit to the binding curve from which the binding affinity 
(KD), dissociation rate constant (kd), association rate constant (ka), maximum 
response (Rmax), and mass transport coefficient (km) are calculated (Figure 6).  
KD = 29.701mM. Rmax = 2,395.5. ka = 53.15. kd = 1.579. km = 8881.8. The second 
method used the affinity analysis to find the KD based on the steady state of each 
Figure 5: Ethanol dilutions 
Shows the ethanol dilutions from left to right: 1%, 
0.25%, 0.25%, 0.0625% and, 0.0625%.  
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curve between the different calibrations (Figure 7).  From this method KD = 
29.2mM. Rmax = 2300.1. 
RUN 1 
 The first SPR run for analysis of the kinetics between the VEGF-A and the 
anti-VEGF-A antibody and anti-VEGF-A aptamer (Figure 8). There was no 
binding between the molecules observed. The large downward curve was 
caused by the bulk flow of the liquid in the injected sample, the portion were the 
binding would have occurred is the bottom of the curve. If interaction had 
Figure 6: SPR analysis fit curves 
Shows the fit of the curve to the ethanol 
concentrations, those for 1% and 0.25% are 
much better than for 0.0625%. From these 
curves the kinetic binding between the gold 
and the ethanol can be determined. 
Figure 7: Affinity of ligand curve 
Shows the affinity curve between the 
ethanol and the gold chip surface, 
calculated using the concentrations of the 
ethanol. 
Figure 8: Attempted immobilization of VEGF-A 
Shows the activation of the CM-Dextran surface with NHS/EDC solution, the injection of 
the 50nM VEGF-A solution, and the deactivation of the surface with EA. 
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occurred, there would have been a slight increase in the line, however it was flat 
for all sample injections, the NaOH, and even DI H2O (Figure 9).  
RUN 2 
The second SPR run was changed from the first by adjusting the pH of the 
VEGF-A solution from ~7.0 to ~9.0. Even with this adjustment the VEGF-A did 
not immobilize onto the CM-Dextran surface (Figure 10). The VEGF-A upon 
injection had no interaction with the surface. 
RUN 3 
 The third SPR run adjusted the pH of the VEGF-A again, this time to ~4.5. 
The VEGF-A was successfully immobilized onto the CM-Dextran as seen by the 
slight upward curve in the SPR signal after the initial bulk flow curve of the fluid 
(Figure 11).  Due to the fact that channel 1 and channel 2 were not correctly 
calibrated, the kinetics on the molecular binding could not be analyzed. However 
Figure 9: Absence of VEGF-A binding between antibody and aptamer 
Shows an excerpt of the inaction curves between the VEGF-A and the anti-VEGF aptamer 
and the anti-VEGF-A antibody. Since the bottom of the curve is flat, no binding took place. 
Figure 10: Failed immobilization of VEGF-A 
Shows the activation of the CM-Dextran surface, however, the VEGF-A was not immobilize 
onto the surface, evidenced by the lack of an upward signal when the VEGF-A was injected. 
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a qualitative analysis of the 
binding curves may be 
done. Using the computer 
the mDeg change in each 
curve was measured 
(Figure 12).  
RUN 4 
The fourth SPR run was performed to obtain data that would allow for 
quantitative kinetic analysis (Figure 13). A gold chip was used to obtain a new 
calibration where channel 1 = 2034.93 and channel 2= 2090.77 (Table 1). Using 
the new calibrations 0.5M PBS buffer 
was used to calibrate the CM-
Dextran chip using the same 
mathematical process. The initial 
mDeg reading in channel 1 was 
158.160 and in channel 2 was 
184.557. The average was taken to find the ‘ideal’ number from which both 
Figure 11: Successful immobilization of VEGF-A 
Shows the immobilization of the VEGF-A onto the CM-
Dextran. The large downward curve is caused by the 
bulk flow of the fluid in the sample since it is not the 
same as the running buffer. The immobilization of the 
VEGF-A is seen by the slight upward curve magnified 
Figure 13: PBS buffer calibration 
Shows the overall SPR run from calibration 
to injections of the antibody and aptamer. 
Figure 12: Quantitative kinetic analysis of antibody and aptamer 
a. Shows the binding curve between the anti-VEGF-A antibody and the VEGF-A. b. Shows the 
binding curve between the anti-VEGF-A aptamer and the VEGF-A. These curves simply show 
there was binding between the molecules. 
a
. 
b
. 
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channels were to be calibrated:  average = 171.359. The same calibrate 
mathematical process was carried out as with the 1% ethanol and channel 1= 
2171.73 and channel 2= 1966.89. The surface appeared to be functionalized, 
giving a curve similar to Graph 7.  Once the injections of anti-VEGF-A antibody 
and anti-VEGF-A aptamer were completed the kinetic analysis program was 
used to analyze the data. Channel 2 was where the VEGF-A was immobilized 
and channel 1 was used for the reference, the data was imputed into the 
program (Figure 14). The curve was zeroed to align the baselines of both 
channel 1 and channel 2 (Figure 15).Excess data was removed using the 
cropping page in the software.  The date was then aligned.  The reference, 
Table 1: PBS calibration calculations 
Shows the calibrations calculations for 1% ethanol to reach 60mDeg change 
in both channel 1 and channel 2. Once calibrated the channels can be used 
for quantitative data where one channel is a reference to subtract out bulk 
flow interference. 
Channel		1	 3000(60/89.143)=		
2019.23	
2019.23(60/59.537)=	
2034.93	
	
Channel	2	 3000(60/85.815)=		
2097.54	
	
2097.54	(60/61.667)=	
2040.83	
2040.83(60/56.280)=	
2175.73	
Figure 14:  Step 1 of kinetic analysis 
Data is input into program in order to 
determine the binding interactions 
between the VEGF-A and the anti-
VEGF-A ssDNA aptamer. 
a. b. 
Figure 15: Step 2 of the kinetic analysis  
The program zeros the curves so that they 
can be directly compared. a. Shows the 
graph before zeroing took place. b. Shows 
the graph after it is zeroed. 
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channel 1, was subtracted from channel 2 
to reveal the actual binding interaction 
curve between VEGF-A and anti-VEGF-A 
aptamer (Figure 16). A curve was fit to the 
curve from which the kinetic data was found 
(Figure 17). From the data obtained, 
analyzed, and averaged: KD= 24.1nM, km= 
1.76X108, ka= 1.02X1011, kd= 2549, and Rmax=56.7 (Table 2). The 100nM 
antibody was also analyzed using the kinetic software (Figure 18). 
Table 2: Aptamer Kinetics 
Shows the results of the kinetic analysis software for the anti-VEGF-A aptamer.  
Figure 18: Curve of denatured antibody 
Shows the fitted line to the binding curve 
of the interaction between the anti-
VEGF-A and VEGF-A. 
a. b. 
Figure 16: Step 5 of kinetic analysis  
Program subtracted the reference channel from 
the channel where the VEGF-A was 
immobilized. a. Shows the graph before it is 
referenced. b. Shows the graph after it is 
referenced, can finally see the binding curve 
between the VEGF-A and the anti-VEGF-A 
DNA aptamer. 
 
Figure 17: Kinetic curve of aptamer 
Step 6 of the kinetic analysis program fits 
a line to the binding curve. From this 
curve the km, ka, kd, Rmax, and KD are 
calculated. 
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RUN 5 
 Run 5 was done to analyze the kinetics of the anti-VEGF-A antibody, all of 
the same steps were performed as with 
the aptamer until the software fitted a 
line to the binding curve (Figure 19).  
This graph was used to find the kinetic 
properties between the VEGF-A and the 
anti-VEGF-A antibody: KD= 88.4uM, km= 
2.16X108, ka= 1.75X105, kd= 14.78, and 
Rmax=74,617 (Table 3). 
Table 3: Antibody kinetics 
Shows the results of the kinetic analysis of the anti-VEGF-A antibody. 
Figure 19: Kinetic curve of antibody 
Shows the fitted line to the binding curve of 
the interaction between the anti-VEGF-A 
and VEGF-A. 
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V. DISCUSSION 
ETHANOL 
The 1% ethanol gave a measurement of 60mDeg after several calibrations 
of both channel 1 and channel 2. The 0.25% ethanol was ¼ the concentration of 
the 1% ethanol so it was expected to give a response of 15mDeg. The actual 
response was ~15.41mDeg which was very close to the expected. The 0.0625% 
ethanol solution was ¼ of the 0.25% and 1/16 of the 1% solution, so the 
expected mDeg response was 3.75. The actual results were ~4.2mDeg. This 
difference was later explained by the fact that the micropipette used in the 
mixture of the 0.0625% solution was not correctly calibrated, causing the solution 
to be more concentrated that it should have been. It is possible to tell that the 
solution was more and not less concentrated than it should have been because 
the mDeg change was greater than it should have been and not less.   
The calibration and dilution experiment was important because the 
instructions and results were clearly given the BI-2000 Manual and therefore it 
was easy to tell if the experiment had been performed correctly through use of 
the SPR machine. This was an essential step to know before moving onto the 
more complicated experiments where the materials used were much more 
expensive. Mistakes such as the calibration of the micropipette were found prior 
to the following experiments and new one was ordered. Several other SPR runs 
were done using gold chips and ethanol for further experience with the 
equipment and techniques such as the correct amount of immersion oil to be 
used were learned. 
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The ethanol dilution experiment also allowed for the kinetic analysis 
software to be used, when unfamiliar with the steps of the program it is confusing 
and the results do not make sense. Using the ethanol dilutions allowed for 
analysis using both the affinity and the kinetic portions of the software. From the 
affinity analysis it was found that KD = 29.2mM and Rmax = 2300.1. When using 
the kinetic analysis it was found that KD = 29.701mM, Rmax = 2,395.5, ka = 53.15, 
kd = 1.579, and km = 8881.8. While the kinetic analysis results in more data, it is 
possible to compare the KD and Rmax directly between the two methods both of 
which were very close between the two. The differences between these two 
techniques was that the affinity analysis required the use of multiple dilutions of a 
sample and then the software was used to compare the steady-state binding at 
each concentration. The kinetic analysis requires only one sample with a known 
concentration to be used and provides more information. Ideally both methods 
would be used for every experiment since the results for each can be used to 
verify each other.  
The KD≈ 29mM means that there is weak binding between the gold 
surface and the ethanol, most likely due only hydrogen bonding between the two 
as the ethanol is adsorbed to the gold surface as the fluid travels over it. Ideally 
for the binding between a target molecule and its binder, the KD should be as 
small of a number as possible. For something such as the interaction between 
streptavidin and biotin the KD is on the order of fM [42], which is equal to 10-15M.  
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VEGF-A AND ANTI-VEGF-A POLYCLONAL ANTIBODIES SSDNA APTAMER 
Run 1 
 The first SPR run using CM-Dextran and VEGF-A resulted in no 
immobilization of the VEGF-A and therefore not interaction between it and the 
anti-VEGF-A aptamer or anti-VEGF-A polyclonal antibody solutions. This was 
determined by the fact that there was not positive interaction curve when the 
antibody or aptamer were injected into the 1M PBS buffer flow. The aptamer and 
antibody curves were identical, both showing the same downward bulk flow and 
not interaction between the VEGF-A molecules. The Biosensing Instruments 
technical expert was contacted and the negative results were verified it was 
suggested that the VEGF-A was not able to immobilize in the CM-Dextran due to 
the pH of the solution [43]. The technical specialist at Biosensing Instruments 
recommended that the experiment be performed within a pH ±1 from the 
isoelectric point of the protein. The isoelectric point of VEGF-A was found to be 
either 8.5 or 9.2 so the pH of 9 was decided to be used since it was between the 
two pHs.  
 Anther change that was suggested by the technical specialist was to use 
the same solution as the buffer for that which the VEGF-A was in to decrease the 
downward bulk flow curve. Since the entire VEGF-A sample was already diluted 
to 50nM in DI H2O, the sample was further diluted to 25nM. In completely 
optimized SPR runs using immobilized proteins concentrations as low at 10nM 
have been used for immobilization so the decrease in concentration has 
precedent. However, since the VEGF-A experiment could not be optimized as it 
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would use too many materials and therefore cost too much, a higher 
concentration was suggested. In order to compensate for the use of only a 25nM 
solution of VEGF-A, multiple injections of samples were to be used to increase 
the possible amount of protein that could be immobilized.  
 It was determined that both the CM-Dextran chips and the chemicals in 
the activation kit were still viable, an important determination since the CM-
Dextran chips were labeled ‘for best use’ before February and the experiment 
was being run in early April.  
Run 2 
Changing the pH of the VEGF-A solution from ~7.0 to 9.0 did not result in 
the immobilization of the VEGF-A into the CM-Dextran on the chip surface. When 
immobilizing a protein on the surface of CM-Dextran it is important to take into 
consideration not only the isoelectric point of the protein but of the CM-Dextran. 
When the pH of a solution containing a protein is less than the isoelectric of the 
protein the net charge of the protein is positive and when the pH is greater than 
the isoelectric point of the protein the net charge will be negative.  This is 
important because the CM-Dextran surface is negative when the pH of the 
solution is greater than 3.5, in order for the VEGF-A protein to be able to 
immobilize on the surface the pH should be higher than 3.5 but lower that the 
isoelectric point of the VEGF-A. In run 2, where the pH was 9.0, if the protein had 
the isoelectric point of 8.5, that meant that it had a negative net charge and the 
CM-Dextran had a negative net charge. This would result in the repulsion of the 
VEGF-A from the surface of the CM-Dextran, inhibiting immobilization (Figure 
 49
20). Using this 
information, a new 
pH of ~4.5 was 
selected for the 
VEGF-A solution to 
complement 
immobilization. 
Run 3 
 In run 3, immobilization of the VEGF-A occurred, indicating that the pH of 
the VEGF-A solution was the problem inhibiting immobilization in run 1 and run 2.  
This immobilization was verified by the upward binding curve after the initial 
downward bulk flow of the VEGF-A solution was injected into the 1M PBS buffer 
flow. Due to the 25nM concentration three injections of the VEGF-A were used. 
In order to prove binding, an injection of pH 9.3 VEGF-A was also used, that did 
not immobilize. Due to the fact that the injections were only done in one channel, 
only a qualitative analysis could be done between the aptamer and the antibody. 
Using this initial analysis between the 50nM antibody and 50nM aptamer 
solutions: the kon for the appeared to higher than that of the antibody. The 
aptamer also appears to have a slightly better affinity for the VEGF-A than the 
antibody does because there was a larger mDeg change, indicating a higher KD. 
From the graphs it was not possible to analyze the koff differences between the 
antibody and the aptamer.  To obtain qualitative differences between the anti-
VEGF-A antibody and the anti-VEGF-A aptamer the SPR experiment had to be 
Figure 20: Immobilization of CM-Dextran 
Shows the attraction or repulsion between a protein and the CM-
Dextran surface depending on the pH of the solution. (Provided 
courtesy of GE Healthcare) 
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run again using a fully calibrated machine and using one channel as a reference 
to subtract the bulk flow from the actual interaction curve. 
Run 4  
 The technical specialist at Biosensing Instruments was consulted on how 
to calibrate the SPR machine for CM-Dextran chips verse gold chips: using the 
initial calibration numbers obtained using a normal gold chip, a 50% dilution of 
the running buffer should be used to further calibrate the CM-Dextran chip. Since 
a 1M PBS buffer was being used as the running buffer, a 0.5M PBS solution was 
used to calibrate for the specific CM-Dextran chip. This calibration was 
necessary because in order to use the kinetic analysis software, channel 1 and 
channel 2 need to give the exact same readings. This way, any differences 
between the two can be detected. This is achieved by immobilizing only one 
channel with the VEGF-A, that way only one channel will bind the anti-VEGF-A 
antibody or aptamer and the other channel will only show the interaction of the 
anti-VEGF-A antibody or aptamer with the surface of the CM-Dextran and any 
other bulk flow characteristics.  When using a reference channel it is difficult to 
see any difference in the curve between the channel with the immobilized VEGF-
A and that without. It is not until the data is manipulated using the kinetic analysis 
software that the binding curve becomes apparent. Each of the 100nM anti-
VEGF-A aptamer curves were put into the program so that an average of the 
interactions could be taken to get more accurate results.  
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After the data was zeroed, aligned, cropped, and the reference channel 
subtracted a line was fit from which the software was able to calculate KD= 
24.1nM, km= 1.76X108, ka= 1.02X1011, kd= 2549, and Rmax=56.7. The KD from the 
literature where the anti-VEGF-A aptamer was taken was equal to 20nM, so the 
KD found was very close. This difference could be explained by fact that the 
VEGF-A used in this experiment had a different source than that used in the 
literature. The VEGF-A used in this experiment came from HKE 293 derived 
cells. It was also composed of only amino acid 27-191 of the whole sequence 
that normally makes up VEGF-A. The VEGF-A used in the literature came from 
Sf21 insect cells and there was no data given for if it was composed of the whole 
polypeptide sequence. If any of the missing amino acids composed portions of 
the VEGF-A to where the aptamer bound, that would explain the change from 
20nM to 24.1nM. Either way since the equilibrium dissociation constant (KD) was 
in the nanomolar region, that means that the affinity between the VEGF-A and 
anti-VEGF-A aptamer was very good. Typically the equilibrium dissociation 
constant is between 1X10-5 and 1X10-12. The association rate constant, ka, as 
suggested in the 
qualitative SPR run, at 
1.02X1011 M-1s-1 is very 
high. The association 
rate constant is how well 
the VEGF-A and 
aptamer recognize each 
Figure 21: Kinetic equilibrium 
Shows the relationship between the VEGF-A (B) and the anti-
VEGF-A aptamer (A). The equation is for calculating the 
association rate constant and the dissociation rate constants.  
(Provided courtesy of GE Healthcare) 
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other.  Typical association rate constants are between 1X10-3 and 1X107 M-1s-1. 
The dissociation rate constant at 2549 s-1 is much less than the association rate 
constant and it shows how stable the binding between the VEGF-A and the 
aptamer was. Typical dissociation rate constants are between 1X10-1 and 5X10-6 
s-1.  This suggests that the binding between the VEGF-A and the aptamer is not 
very stable, however the extremely high association constant overcomes this and 
still allows for an overall high equilibrium dissociation constant. Rmax at 56.7 
means maximum binding capacity and represents the total concentration of 
VEGF-A protein immobilized on the CM-Dextran chip. 
 
When the anti-VEGF-A antibody was analyzed it was found that it had 
denatured and was no longer binding to the VEGF-A. This makes sense because 
the antibody solution was being stored at between 2°C and 8°C and on the 
manufacture’s information sheet at that temperature the antibody was only viable 
for around two weeks. This experiment was performed roughly 3 weeks after the 
solution was made. Luckily, some of the 100nM antibody solution was being 
stored at -20°C, where it is stable for up to a year.  However, this shows one of 
the limitations between using antibodies instead of aptamers, the aptamer was 
still stable even after three weeks of storage at a higher temperature. In some 
places where temperature control is not easily available this could be a huge 
incentive to use aptamers over antibodies. In order to determine exactly how 
much longer aptamers last than antibodies additional testing would be required 
for this particular antibody/aptamer grouping.  
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Run 5  
 Since the antibody used in run 4 had denatured, another SPR run was 
performed to get usable data for direct comparison between the antibody and the 
aptamer. In order to ensure that the VEGF-A was still viable and that there was 
enough for the anti-VEGF-A antibody to bind to the 150nM solution was used. 
Using this concentration would provide ample binding sites to analyze the 
antibody; even at this concentration 4 injections of the VEGF-A were made. This 
precaution was also taken because the antibody had been giving another 
researcher problems with ability to bind with the VEGF-A. The results found were 
that KD= 88.4uM, km= 2.16X108, ka= 1.75X105, kd= -14.78, and Rmax=74,617. The 
Rmax, is noticeably higher than that with the aptamer, this is due to the use of the 
150nM VEGF-A solution instead of the 25nM solution as over 1000 times the 
amount of VEGF-A was immobilized on the CM-Dextran surface. The KD at 
88.4uM has a magnitude of 1000 times less affinity for VEGF-A than the anti-
VEGF-A aptamer.  The association rate constant at 1.75X105 M-1s-1 for the anti-
VEGF-A antibody was also significantly less than that of the aptamer, meaning 
that the antibody did not recognize the VEGF-A as well. The kd for the antibody 
was 14.17 s-1 meaning that the stability between the VEGF-A and the anti-VEGF-
A antibody was higher than that between the VEGF-A and the aptamer, though 
still not low enough to truly be stable.   
Antibody verses aptamer 
Figure 22 shows the difference between high-affinity and lower-affinity 
curves. The anti-VEGF-A aptamer follow the high-affinity curve with a high ka and 
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a high kd. The anti-VEGF-A 
antibody follows the lower-
affinity curve by having both a 
low ka and a low kd. Therefore 
the aptamer had the overall 
highest affinity for the VEGF-A 
by a significant amount making 
it the better option between the 
two based on binding affinities.  
While in this experiment the aptamer had a much higher affinity for the 
VEGF-A in some literature there have been antibodies modified to have affinities 
less than 1nM [33]. One possible reason that the affinity between the VEGF-A 
and the anti-VEGF-A antibody was so poor was because it was a polyclonal 
antibody solution; while the antibodies were created for VEGF-A there was no 
screening method to select for high affinity binding antibodies in the solution. As 
seen in Table 3, the KD is much lower in the 80nM solution that it was in the 
100nM solution; perhaps this was because the 80nM solution had more 
antibodies with higher affinity for the VEGF-A than were in the 100nM solution.  
Ideally for direct comparison between aptamers and antibodies, a  
SPR for analysis 
 SPR offers many advantages for protein and analyte binding analysis. 
When compared to techniques such as ELISA and RIA (relative affinity index), 
SPR offs a much quicker methodology. In addition, there are no other laboratory 
Figure 22: High and low affinity curves 
The upper curve shows a high-affinity curve where 
ka is high and kd is high. The lower curve shows a 
lower-affinity curve where ka is low and kd is high. A 
high ka means there is fast association and a high kd 
means there is fast dissociation. (From Bio Rad 
“Protein Interaction Analysis”) 
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techniques that offer the same level of kinetic analysis. Traditionally 
spectrophotometers have been used to observe kinetics but not in the same real-
time way. The fact that only uL of sample is required at concentrations in the nM 
range means that this method can be used for analyzing costly materials without 
high cost.  
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VI. CONCLUSION 
Depending on what function the antibody or aptamer is to be used for will 
depend on which should be used, however, aptamers have the same function 
ability as antibodies do while offering easier modifications and more stability.   
Antibodies have long been limited by the fact that they need to maintain 
conditions similar to those within the body. Temperature it one of the main 
methods through which antibodies are irreversibly denatured; this comes into 
paly when being used for diagnostic applications, for example, pregnancy tests 
have a shelf life of 12-24 months when stored at room temperature (between 2°C 
and 30°C).  If a test is being created for in the field testing in a country with 
temperatures continually above 30°C where there is limited access to 
refrigeration then antibody assays are not going to function for their entire shelf 
life. Aptamers on the other hand can be regenerated from their denatured form 
and are stable in long-term storage and allow for transportation in various 
temperatures [45]. The temperature of denaturation for nucleic acid sequences 
depends on what order the nucleic acids is in, since aptamers that are 
engineered for a specific molecule can have different sequences, the one with 
the most stability in high temperatures can be selected in order to optimize it.  
Another advantage of aptamers over antibodies is that they can be 
created to molecules that are toxic to cells. This allows for applications of the 
aptamer to be expanded beyond that of antibodies to testing devices for toxic 
chemicals within the environment.  Antibodies during their production cannot be 
produced to something that will kill the cell or animal it is being produced in, since 
 57
aptamers are produced in the lab without the use of cells they do not face this 
problem. Labeled aptamers could be used to determine the purity of a water 
sample by creating a group of aptamers that testing for certain bacteria, heavy 
metals or other contaminants and that will activate if bound. 
Due to the high level of modifications for aptamers, they offer to be and 
ideal molecules for cell targeting.  The process of Counter-SELEX has already 
been used to develop aptamers that will target only cells with cancer, while 
leaving alone those that are healthy. Since aptamers can be modified, there is 
potential for them to be used for targeted drug delivery of chemotherapy to 
cancerous cells, eliminating many of the negative side effects that accompany 
the traditional use of chemotherapy. A similar application of aptamers could 
result in the targeting of HIV infected cells and destroying them before spread to 
other T cells and the patient advances to AIDS. Another application would be to 
use differently labeled aptamers that bind to different types of cells for use in 
surgery, by creating differently fluoresced aptamers for different cell types it 
would be possible to avoid certain cell types, such as nerves to reduce damage 
to the body. 
Future research that could apply the information learned about the kinetics 
of the anti-VEGF-A antibody and anti-VEGF-A aptamer. For example, lateral flow 
immunological assays could be developed using the aptamer, since its affinity is 
significantly better than the antibody. Monoclonal antibodies and MIPs should 
also be analyzed using SPR in order to directly compare with the results already 
obtained. Once all this information is ascertained, the molecules with the best 
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binding could be used to create a portable, stable, and quick diagnostic assay. 
Similar testing could also be used to select for the best molecule choice in other 
diagnostics besides with VEGF-A.
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APPENDIX 
A. CALCULATIONS 
Molecular weights for all 
materials 
Calculations for the NaOH solution 
Calculation for the 150nM VEGF solution 
Calculation for the 100nM antibody solution 
Calculation for the 100nM aptamer solution 
 63
Calculation for the 50nM solutions 
Calculation for the 25nM solutions 
Calculation for the HCl solution 
Calculations for attempting to change the pH to 8.6, the PBS buffer resisted 
the change of pH so pH was changed using a pH probe  
 64
 B. SPR ETHANOL RAW DATA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Overall ethanol dilution experiment 
mDeg of the 1% ethanol  solution 
 65
 
mDeg of the 0.25% ethanol solution 
mDeg of the 0.0625% ethanol solution 
 66
Ethanol curves input into the BI-Analysis program 
Zeroing page of the ethanol analysis 
 67
Cropping page of the ethanol analysis 
Alignment page of the ethanol analysis 
 68
Analyte bound page of the ethanol analysis 
Affinity page of the ethanol analysis 
 69
Kinetics page of the ethanol analysis page 1 
Kinetics page of the ethanol analysis page 2 
 70
C. SPR RUN 1 RAW DATA 
Activation of CM-Dextran and attempted immobilization of VEGF-A 
Overall injections of sample for Run 1 page 1 
 71
 
Overall injections of sample for Run 1 page 2 
 72
 
D. SPR RUN 2 RAW DATA 
 
 
Activation of CM-Dextran surface and attempted immobilization of 
VEGF-A 
 73
 
E. SPR RUN 3 RAW DATA 
Overall SPR Run 3 
Immobilization of VEGF-A 
 74
 
 
Run 3 injections page 1 
Run 3 injections page 2 
 75
Run 3 injections page 3 
100nM antibody qualitative analysis 
 76
 
100nM aptamer qualitative analysis 
 
50nM antibody qualitative analysis 
 
 77
50nM aptamer qualitative analysis 
 
25nM antibody qualitative analysis 
 
 78
 
  
 
 
25nM aptamer qualitative analysis 
 
 79
F. SPR RUN 4 RAW DATA 
Overall SPR Run 4 
 
Activation of the CM-Dextran and immobilization of VEGF-A 
 
 80
 
VEGF-A immobilization curve 
 
Run 4 Injections  
 
 81
 
100nM binding curve 
 
100nM aptamer kinetic analysis page 1 
 82
 
100nM aptamer kinetic analysis page 2 
100nM aptamer kinetic analysis page 3 
 83
 
100nM aptamer kinetic analysis page 4 
100nM aptamer kinetic analysis page 5 
 84
 
100nM aptamer kinetic analysis page 6 
100nM aptamer kinetic analysis 2 
 85
G. SPR RUN 5 RAW DATA 
 
 
Overall SPR Run 5 
Run 5 injections page 1 
 86
 
 
Run 5 injections page 2 
100nM antibody binding curve 
 87
 
Selection of the curve to be analyzed and the reference to be 
100nM antibody kinetic analysis page 1 
 88
 
100nM antibody kinetic analysis page 2 
100nM antibody kinetic analysis page 3 
 89
100nM antibody kinetic analysis page 4 
100nM antibody kinetic analysis page 5 
 90
100nM antibody kinetic analysis page 6 
100nM antibody kinetic analysis page 7 
 91
100nM antibody kinetic analysis 2 
 92
H. VEGF INFORMATION SHEET 
 
 
 
 
 
 
 
 
 
 
 
 
 93
I. ANTIBODY INFORMATION SHEET 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 94
 
 95
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J. BI ANALYSIS SOFTWARE PROTOCOL 
All data is from ethanol dilutions experiment from protocol except for Step 2 and 
Step 7. 
 
Step 1: Open raw date curves from 
experiment. (Figure 1) 
 
 
 
 
 
 
 
 
 
 
 
 
Step 2: Select curve and reference 
curve. (Figure 2)  
 
 
 
 
 
 
 
 
 
 
 
 
 
Step 3: Enter concentrations of solutions 
injected. For example: if 30nM solution 
was used, enter 30n. For example, if 3 
dilutions were made, enter concentration 
into ‘Bulk conc’ and then the dilution 
factor, and then 1, 2, 3 for each 
concurrent dilution: bulk concentration 
=1% (0.01) and dilutions of 1/4 are made, 
enter 1 for 1% and 2 for 1/4 dilution and 3 
for 1/16. (Figure 3) 
 
 
Figure 1 
Figure 3 
Figure 2 
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Step 4:  Zero the data by placing the 
green and then red lines over an area of 
the curve that is flat for each curve. 
(Figure 4) 
 
 
 
 
 
 
 
 
 
 
 
 
Step 5: Crop the data to remove excess 
from each side by moving the green line 
to crop at the beginning and the red line 
to crop at the end. (Figure 5) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Step 6: Align the data by placing the 
green line at the beginning of the first 
curve and the red line at the peak of the 
last curve to remove any variation in time 
due to channels. (Figure 6) 
 
 
 
 
 
 
 
Figure 4 
Figure 5 
Figure 6 
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Step 7: Subtract the reference channel 
from the channel where sample was 
bound (channel 1-channel 2 or channel 2- 
channel 1). (Figure 7) 
 
 
 
 
 
 
 
 
 
 
 
 
Step 8: Bound ligand is calculated by 
placing the green and red lines where 
each curve is at steady state. (Figure 8) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Step 9: Computer calculates the affinity, 
KD and Rmaz. Also shows the curve of 
bound ligand at steady state verses the 
concentration. (Figure 9) 
 
 
 
 
 
 
 
 
 
Figure 8 
Figure 9 
Figure 7 
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Step 10: Fit the orange lines to the data 
curves and the kinetic data KD, ka, kd, 
Rmac, km are calculated. How well the line 
fits the curve is shown by either a red or 
green bar above the results. The green 
line is placed where the curve begins ad 
the red line is placed where the steady 
state ends and the curve drops back 
down. (Figure 10) 
 
 
 
 
 
 
 
 
Step 11: Can then view all results on the Results pag
Figure 10 
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